Agostino Consoli

List of Publications by Year
in descending order

92 papers	8,357 citations	117571 34 h-index	45285 90 g-index
100 all docs	100 docs citations	100 times ranked	9870 citing authors

#	Article	IF	Citations
1	Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. New England Journal of Medicine, 2016, 375, 1834-1844.	13.9	3,898
2	In Vivo Formation of 8-Iso-Prostaglandin F _{2Î±} and Platelet Activation in Diabetes Mellitus. Circulation, 1999, 99, 224-229.	1.6	721
3	Efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes (DEPICT-1): 24 week results from a multicentre, double-blind, phase 3, randomised controlled trial. Lancet Diabetes and Endocrinology,the, 2017, 5, 864-876.	5.5	244
4	Effects on the incidence of cardiovascular events of the addition of pioglitazone versus sulfonylureas in patients with type 2 diabetes inadequately controlled with metformin (TOSCA.IT): a randomised, multicentre trial. Lancet Diabetes and Endocrinology,the, 2017, 5, 887-897.	5.5	231
5	Mechanisms of uremic erythrocyte-induced adhesion of human monocytes to cultured endothelial cells. Journal of Cellular Physiology, 2007, 213, 699-709.	2.0	184
6	Glucagonâ€like peptideâ€1 receptor agonists in type 2 diabetes treatment: are they all the same?. Diabetes/Metabolism Research and Reviews, 2019, 35, e3070.	1.7	161
7	Plasma Exosome MicroRNA Profiling Unravels a New Potential Modulator of Adiponectin Pathway in Diabetes: Effect of Glycemic Control. Journal of Clinical Endocrinology and Metabolism, 2014, 99, E1681-E1685.	1.8	150
8	Plasminogen Activator Inhibitor Type 1 Is Increased in the Arterial Wall of Type II Diabetic Subjects. Arteriosclerosis, Thrombosis, and Vascular Biology, 2001, 21, 1378-1382.	1.1	134
9	An Increased Osteoprotegerin Serum Release Characterizes the Early Onset of Diabetes Mellitus and May Contribute to Endothelial Cell Dysfunction. American Journal of Pathology, 2006, 169, 2236-2244.	1.9	129
10	Soluble RAGE in type 2 diabetes: Association with oxidative stress. Free Radical Biology and Medicine, 2007, 43, 511-518.	1.3	125
11	Acute hyperglycemia and acute hyperinsulinemia decrease plasma fibrinolytic activity and increase plasminogen activator inhibitor type 1 in the rat. Acta Diabetologica, 2001, 38, 71-76.	1.2	119
12	G972R IRS-1 Variant Impairs Insulin Regulation of Endothelial Nitric Oxide Synthase in Cultured Human Endothelial Cells. Circulation, 2004, 109, 399-405.	1.6	104
13	Thromboxane-Dependent CD40 Ligand Release in Type 2 Diabetes Mellitus. Journal of the American College of Cardiology, 2006, 47, 391-397.	1.2	102
14	The Mammalian Tribbles Homolog TRIB3, Glucose Homeostasis, and Cardiovascular Diseases. Endocrine Reviews, 2012, 33, 526-546.	8.9	100
15	Dehydroepiandrosterone Mimics Acute Actions of Insulin to Stimulate Production of Both Nitric Oxide and Endothelin 1 via Distinct Phosphatidylinositol 3-Kinase- and Mitogen-Activated Protein Kinase-Dependent Pathways in Vascular Endothelium. Molecular Endocrinology, 2006, 20, 1153-1163.	3.7	94
16	Insulin enhances vascular cell adhesion molecule-1 expression in human cultured endothelial cells through a pro-atherogenic pathway mediated by p38 mitogen-activated protein-kinase. Diabetologia, 2004, 47, 532-536.	2.9	89
17	Exercise-Induced Improvement in Vasodilatory Function Accompanies Increased Insulin Sensitivity in Obesity and Type 2 Diabetes Mellitus. Journal of Clinical Endocrinology and Metabolism, 2006, 91, 4903-4910.	1.8	85
18	Glucagon dose-response curve for hepatic glucose production and glucose disposal in type 2 diabetic patients and normal individuals. Metabolism: Clinical and Experimental, 2002, 51, 1111-1119.	1.5	76

#	Article	IF	Citations
19	Cardiovascular safety of oral semaglutide in patients with type 2 diabetes: Rationale, design and patient baseline characteristics for the PIONEER 6 trial. Diabetes, Obesity and Metabolism, 2019, 21, 499-508.	2.2	71
20	Effects of Liraglutide on Weight Loss, Fat Distribution, and Î²-Cell Function in Obese Subjects With Prediabetes or Early Type 2 Diabetes. Diabetes Care, 2017, 40, 1556-1564.	4.3	69
21	Decreased in vivo oxidative stress and decreased platelet activation following metformin treatment in newly diagnosed type 2 diabetic subjects. Diabetes/Metabolism Research and Reviews, 2008, 24, 231-237.	1.7	66
22	Glucose and insulin independently reduce the fibrinolytic potential of human vascular smooth muscle cells in culture. Diabetologia, 1996, 39, 1425-1431.	2.9	65
23	Do thiazolidinediones still have a role in treatment of type 2 diabetes mellitus?. Diabetes, Obesity and Metabolism, 2013, 15, 967-977.	2.2	65
24	Features of endothelial dysfunction in umbilical cord vessels of women with gestational diabetes. Nutrition, Metabolism and Cardiovascular Diseases, 2014, 24, 1337-1345.	1.1	56
25	Thiazolidinediones and inflammation. Lupus, 2005, 14, 794-797.	0.8	55
26	Liraglutide improves memory in obese patients with prediabetes or early type 2 diabetes: a randomized, controlled study. International Journal of Obesity, 2020, 44, 1254-1263.	1.6	54
27	TRIB3 R84 Variant Is Associated With Impaired Insulin-Mediated Nitric Oxide Production in Human Endothelial Cells. Arteriosclerosis, Thrombosis, and Vascular Biology, 2008, 28, 1355-1360.	1.1	53
28	Circulating Dickkopfâ€1 in Diabetes Mellitus: Association With Platelet Activation and Effects of Improved Metabolic Control and Lowâ€Dose Aspirin. Journal of the American Heart Association, 2014, 3, .	1.6	53
29	Phenotype modulation in cultures of vascular smooth muscle cells from diabetic rats: Association with increased nitric oxide synthase expression and superoxide anion generation. Journal of Cellular Physiology, 2003, 196, 378-385.	2.0	52
30	Effect of an l-Carnitineâ€“Containing Peritoneal Dialysate on Insulin Sensitivity in Patients Treated With CAPD: A 4-Month, Prospective, Multicenter Randomized Trial. American Journal of Kidney Diseases, 2013, 62, 929-938.	2.1	42
31	Potential side effects to GLP-1 agonists: understanding their safety and tolerability. Expert Opinion on Drug Safety, 2015, 14, 207-218.	1.0	41
32	Liraglutide mitigates TNFâ€Î± induced proâ€atherogenic changes and microvesicle release in HUVEC from diabetic women. Diabetes/Metabolism Research and Reviews, 2017, 33, e2925.	1.7	41
33	Skeletal muscle is a major site of lactate uptake and release during hyperinsulinemia. Metabolism: Clinical and Experimental, 1992, 41, 176-179.	1.5	37
34	Fasting Hyperglycemia Normalizes Oxidative and Nonoxidative Pathways of Insulin-Stimulated Glucose Metabolism in Noninsulin-Dependent Diabetes Mellitus*. Journal of Clinical Endocrinology and Metabolism, 1990, 71, 1544-1551.	1.8	36
35	Transcriptome analysis of human primary endothelial cells (HUVEC) from umbilical cords of gestational diabetic mothers reveals candidate sites for an epigenetic modulation of specific gene expression. Genomics, 2014, 103, 337-348.	1.3	36
36	Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) regulates endothelial nitric oxide synthase (eNOS) activity and its localization within the human vein endothelial cells (HUVEC) in culture. Journal of Cellular Biochemistry, 2006, 97, 782-794.	1.2	32

#	Article	IF	Citations
37	Use and effectiveness of dapagliflozin in routine clinical practice: An Italian multicentre retrospective study. Diabetes, Obesity and Metabolism, 2018, 20, 1781-1786.	2.2	32
38	The Prominent Role of P38 Mitogen-Activated Protein Kinase in Insulin-Mediated Enhancement of VCAM-1 Expression in Endothelial Cells. International Journal of Immunopathology and Pharmacology, 2007, 20, 539-555.	1.0	31
39	The TRIB3 R84 variant is associated with increased carotid intimaâ€“media thickness in vivo and with enhanced MAPK signalling in human endothelial cells. Cardiovascular Research, 2011, 89, 184-192.	1.8	28
40	Contribution of Gluconeogenesis to Overall Glucose Output in Diabetic and Nondiabetic Men. Annals of Medicine, 1990, 22, 191-195.	1.5	27
41	A comparative safety review between GLP-1 receptor agonists and SGLT2 inhibitors for diabetes treatment. Expert Opinion on Drug Safety, 2018, 17, 293-302.	1.0	27
42	Glucose-lowering therapy and cardiovascular outcomes in patients with type 2 diabetes mellitus and acute coronary syndrome. Diabetes and Vascular Disease Research, 2019, 16, 399-414.	0.9	26
43	Joint effect of insulin signaling genes on cardiovascular events and on whole body and endothelial insulin resistance. Atherosclerosis, 2013, 226, 140-145.	0.4	23
44	Inositol and antioxidant supplementation: Safety and efficacy in pregnancy. Diabetes/Metabolism Research and Reviews, 2019, 35, e3154.	1.7	23
45	ENPP1 Q121 Variant, Increased Pulse Pressure and Reduced Insulin Signaling, and Nitric Oxide Synthase Activity in Endothelial Cells. Arteriosclerosis, Thrombosis, and Vascular Biology, 2009, 29, 1678-1683.	1.1	22
46	Adherence of uremic erythrocytes to vascular endothelium decreases endothelial nitric oxide synthase expression. Kidney International, 2005, 67, 1899-1906.	2.6	21
47	Thromboxane-Dependent Platelet Activation in Obese Subjects with Prediabetes or Early Type 2 Diabetes: Effects of Liraglutide- or Lifestyle Changes-Induced Weight Loss. Nutrients, 2018, 10, 1872.	1.7	19
48	Enrolment criteria for diabetes cardiovascular outcome trials do not inform on generalizability to clinical practice: The case of glucagonâ€like peptideâ€1 receptor agonists. Diabetes, Obesity and Metabolism, 2020, 22, 817-827.	2.2	19
49	Plasma microRNA signature associated with retinopathy in patients with type 2 diabetes. Scientific Reports, 2021, 11, 4136.	1.6	19
50	Selective Insulin Resistance Affecting Nitric Oxide Release But Not Plasminogen Activator Inhibitor-1 Synthesis in Fibroblasts From Insulin-Resistant Individuals. Arteriosclerosis, Thrombosis, and Vascular Biology, 2005, 25, 2392-2397.	1.1	18
51	The C242T polymorphism of the p22phox component of NAD (P)H oxidase and vascular risk. Thrombosis and Haemostasis, 2008, 99, 594-601.	1.8	18
52	Novel antidiabetic drugs and cardiovascular risk: Primum non nocere. Nutrition, Metabolism and Cardiovascular Diseases, 2016, 26, 759-766.	1.1	18
53	A Functional Variant of the Dimethylarginine Dimethylaminohydrolase-2 Gene Is Associated with Insulin Sensitivity. PLoS ONE, 2012, 7, e36224.	1.1	17
54	Cardiovascular biomarkers in clinical studies of type 2 diabetes. Diabetes, Obesity and Metabolism, 2018, 20, 1350-1360.	2.2	17

#	Article	IF	Citations
55	Similar effectiveness of dapagliflozin and GLPâ€1 receptor agonists concerning combined endpoints in routine clinical practice: A multicentre retrospective study. Diabetes, Obesity and Metabolism, 2019, 21, 1886-1894.	2.2	17
56	Positioning sulphonylureas in a modern treatment algorithm for patients with type 2 diabetes: Expert opinion from a European consensus panel. Diabetes, Obesity and Metabolism, 2020, 22, 1705-1713.	2.2	17
57	Comparative effectiveness of dapagliflozin vs <scp>DPP</scp>â€4 inhibitors on a composite endpoint of <scp>HbA1c</scp>, body weight and blood pressure reduction in the real world. Diabetes/Metabolism Research and Reviews, 2021, 37, e3353.	1.7	17
58	Updated Recommendations on Cardiovascular Prevention in 2022: An Executive Document of the Italian Society of Cardiovascular Prevention. High Blood Pressure and Cardiovascular Prevention, 2022, 29, 91-102.	1.0	17
59	Magnetic Resonance Imaging Determined Visceral Fat Reduction Associates with Enhanced IL-10 Plasma Levels in Calorie Restricted Obese Subjects. PLoS ONE, 2012, 7, e52774.	1.1	16
60	A Decision Support Tool for Appropriate Glucose-Lowering Therapy in Patients with Type 2 Diabetes. Diabetes Technology and Therapeutics, 2015, 17, 194-202.	2.4	15
61	Myoinositol Reduces Inflammation and Oxidative Stress in Human Endothelial Cells Exposed In Vivo to Chronic Hyperglycemia. Nutrients, 2021, 13, 2210.	1.7	15
62	In vivo thromboxaneâ€dependent platelet activation is persistently enhanced in subjects with impaired glucose tolerance. Diabetes/Metabolism Research and Reviews, 2020, 36, e3232.	1.7	14
63	Recommendations for Cardiovascular Prevention During the Sars-Cov-2 Pandemic: An Executive Document by the Board of the Italian Society of Cardiovascular Prevention. High Blood Pressure and Cardiovascular Prevention, 2020, 27, 373-377.	1.0	14
64	Effects of multiple daily injection therapy with humalog mixtures versus separately injected insulin lispro and NPH insulin in adults with type I diabetes mellitus. Clinical Therapeutics, 2004, 26, 502-510.	1.1	11
65	Why Miss the Chance? Incidental Findings while Telescreening for Diabetic Retinopathy. Ophthalmic Epidemiology, 2020, 27, 237-245.	0.8	10
66	Transmural distribution of antioxidant defences and lipid peroxidation in the rabbit left ventricular myocardium. Pflugers Archiv European Journal of Physiology, 1994, 427, 432-436.	1.3	8
67	Exenatide Once Weekly: Effectiveness, Tolerability, and Discontinuation Predictors in a Real-world Setting. Clinical Therapeutics, 2020, 42, 1738-1749.e1.	1.1	8
68	Consensus report of the joint workshop of the Italian Society of Diabetology, Italian Society of Periodontology and Implantology, Italian Association of Clinical Diabetologists (SID-SIdP-AMD). Nutrition, Metabolism and Cardiovascular Diseases, 2021, 31, 2515-2525.	1.1	8
69	Deletion of Gly723 in the insulin receptor substrate-1 of a patient with noninsulin-dependent diabetes mellitus. , 1996, 7, 364-366.		7
70	Novel mutations in GCK and HNF1A genes in Italian families with MODY phenotype. Diabetes Research and Clinical Practice, 2009, 83, e72-e74.	1.1	7
71	Management of type 2 diabetes for prevention of cardiovascular disease. An expert opinion of the Italian Diabetes Society. Nutrition, Metabolism and Cardiovascular Diseases, 2020, 30, 1926-1936.	1.1	7
72	Delphi-Based Consensus on Treatment Intensification in Type 2 Diabetes Subjects Failing Basal Insulin Supported Oral Treatment: Focus on Basal Insulinâ€‰+â€‰GLP-1 Receptor Agonist Combination Therapies. Diabetes Therapy, 2021, 12, 781-800.	1.2	7

#	Article	IF	Citations
73	Beneficial effects of glucagon-like peptide 1 receptor agonists on glucose control, cardiovascular risk profile, and non-alcoholic fatty liver disease. An expert opinion of the Italian diabetes society. Nutrition, Metabolism and Cardiovascular Diseases, 2021, 31, 3257-3270.	1.1	7
74	Diabetes mellitus induces decreased plasma fibrinolytic activity and increased tissue synthesis of plasminogen activator inhibitor-1 (PAI-1) in the rat. Fibrinolysis and Proteolysis, 2000, 14, 261-267.	1.1	5
75	Cardiovascular risk management in type 2 diabetes mellitus: A joint position paper of the Italian Cardiology (SIC) and Italian Diabetes (SID) Societies. Nutrition, Metabolism and Cardiovascular Diseases, 2021, 31, 1671-1690.	1.1	5
76	Hypochlorous Acid-Induced Zinc Release from Thiolate Bonds: a Potential Protective Mechanism Towards Biomolecules Oxidant Damage During Inflammation. Free Radical Research, 1994, 20, 165-170.	1.5	4
77	Effects of liraglutide vs. lifestyle changes on soluble suppression of tumorigenesis-2 (sST2) and galectin-3 in obese subjects with prediabetes or type 2 diabetes after comparable weight loss. Cardiovascular Diabetology, 2022, 21, 36.	2.7	4
78	Semaglutide reduces cardiovascular events regardless of metformin use: a post hoc subgroup analysis of SUSTAIN 6 and PIONEER 6. Cardiovascular Diabetology, 2022, 21, 64.	2.7	4
79	IDegLira for the Real-World Treatment of Type 2 Diabetes in Italy: Protocol and Interim Results from the REX Observational Study. Diabetes Therapy, 2022, 13, 1483-1497.	1.2	4
80	Effectiveness and Tolerability of Once-Weekly GLP-1 Receptor Agonists in Clinical Practice: A Focus on Switching Between Once-Weekly Molecules in Type 2 Diabetes. Frontiers in Endocrinology, 0, 13, .	1.5	4
81	Insulin requirement of simple and complex carbohydrate foods in type 1 (insulin-dependent) CSII-treated diabetic subjects, obtained by Biostator. Correlation with glycaemic index. Acta Diabetologica, 1991, 28, 47-53.	1.2	3
82	Heightened free radical activity in angina pectoris. American Journal of Cardiology, 1993, 72, 830-831.	0.7	3
83	Transposition of cardiovascular outcome trial effects to the real-world population of patients with type 2 diabetes. Cardiovascular Diabetology, 2021, 20, 103.	2.7	3
84	A guide for the use of LibreView digital diabetes platform in clinical practice: Expert paper of the Italian Working Group on Diabetes and Technology. Diabetes Research and Clinical Practice, 2022, 187, 109867.	1.1	3
85	To the editor. Metabolism: Clinical and Experimental, 1993, 42, 262-264.	1.5	2
86	Insulin Resistance Affects Gene Expression in Endothelium. Arteriosclerosis, Thrombosis, and Vascular Biology, 2008, 28, e7-9.	1.1	2
87	Insulin resistance and NAFLD may influence memory performance in obese patients with prediabetes or newly-diagnosed type 2 diabetes. Nutrition, Metabolism and Cardiovascular Diseases, 2021, 31, 2685-2692.	1.1	2
88	Health care organization and use of technological devices in people with diabetes in Italy: Results from a survey of the Working Group on Diabetes and Technology. Nutrition, Metabolism and Cardiovascular Diseases, 2022, 32, 2392-2398.	1.1	2
89	Old and New Biomarkers Associated with Endothelial Dysfunction in Chronic Hyperglycemia. Oxidative Medicine and Cellular Longevity, 2021, 2021, 1-13.	1.9	1
90	Teleretinography into diabetes integrated care: an Italian experience. Annali Dell'Istituto Superiore Di Sanita, 2016, 52, 598-602.	0.2	1

#	Article	IF	Citations
91	Liraglutide: ruolo nel trattamento del diabete di tipo 2. L Endocrinologo, 2009, 10, 102-105.	0.0	0
92	Welcoming teleretinography into diabetes integrated care. European Journal of Ophthalmology, 2021, , 112067212110393.	0.7	0